SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC.

SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC.

AIM: The role of Sirtuin 1 (SIRT 1) in carcinogenesis is controversial. This study was to explore the association between the SIRT1 expression and the clinical characteristics, the responsiveness to chemotherapy and prognosis in Non-small cell lung cancer (NSCLC). METHODS: We enrolled 295 patients w...

Full description

Bibliographic Details
Main Authors:	Tao Zhang, Ningning Rong, Juan Chen, Chengwei Zou, Haiyan Jing, Xiaolong Zhu, Wenlong Zhang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3818418?pdf=render

Similar Items

OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC
by: Yanzhang Hao, et al.
Published: (2014-01-01)

IGF2R Expression is Associated with the Chemotherapy Response and Prognosis of Patients with Advanced NSCLC
by: Zhennan Tian, et al.
Published: (2014-10-01)

RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC.
by: Xiang Wang, et al.
Published: (2012-01-01)

Notch 3 Protein, not its Gene Polymorphism, is Associated with the Chemotherapy Response and Prognosis of Advanced NSCLC Patients
by: Chunlei Shi, et al.
Published: (2014-08-01)

Treatment of Advanced NSCLC with Unknown EGFR Gene Status __ TKI or Chemotherapy?
by: Xiaoqing LIU, et al.
Published: (2014-10-01)

BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC
by: Sun Xian, et al.
Published: (2014-01-01)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)

Chemotherapy and prognosis in advanced thymic carcinoma patients
by: Zhengbo Song, et al.
Published: (2015-12-01)

Efficacy and Safety of rh-Endostatin Combined with Chemotherapy  versus Chemotherapy Alone for Advanced NSCLC: A Meta-analysis Review
by: Jinzhong ZHANG, et al.
Published: (2011-05-01)

Therapeutic pathomorphosis of advanced NSCLC as a criteria for effectiveness of induction chemotherapy.
by: Kosse V.A., et al.
Published: (2007-01-01)

TGFBI expression is associated with a better response to chemotherapy in NSCLC
by: Pío Ruben, et al.
Published: (2010-05-01)

Weekly chemotherapy with cisplatin and paclitaxel in advanced NSCLC: a phase II study
by: G. Buccheri, et al.
Published: (2016-02-01)

SIRT1 expression is associated with poor prognosis of lung adenocarcinoma
by: Li C, et al.
Published: (2015-04-01)

HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC
by: Xiaomei Liu, et al.
Published: (2020-04-01)

HIF1α Genetic Variants and Protein Expressions Determine the Response to Platinum Based Chemotherapy and Clinical Outcome in Patients with Advanced NSCLC
by: Fenglei Wu, et al.
Published: (2013-12-01)

Application of Neoadjuvant Immuno-chemotherapy in NSCLC
by: Si CHEN, et al.
Published: (2021-04-01)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
by: Ya Chen, et al.
Published: (2021-06-01)

Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly
by: Wu C, et al.
Published: (2018-10-01)

Immunotherapeutic Advances for NSCLC
by: Massafra M, et al.
Published: (2021-10-01)

Expressions of c-Cbl, Cbl-b and EGFR and Its Role of Prognosis in NSCLC
by: Xin JIAO, et al.
Published: (2011-06-01)

Effects of estrogen receptor gene expression on susceptibility to DNA damage and prognosis in NSCLC
by: Ling-Ya Lai, et al.
Published: (2000)

Prognostic value of ESR2 expression on adjuvant chemotherapy in completely resected NSCLC.
by: Hongliang Yu, et al.
Published: (2020-01-01)

The role of genetic and other biomarkers in NSCLC prognosis
by: Schveigert Diana, et al.
Published: (2014-06-01)

Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis.
by: Pu-Yun OuYang, et al.
Published: (2013-01-01)

Evaluation of Efficacy of Gefitinib on Advanced non-small-cell Lung Cancer (NSCLC) Resisted to Chemotherapy
by: Jiangjiang TU, et al.
Published: (2008-04-01)

Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma.
by: Chris Zhiyi Zhang, et al.
Published: (2012-01-01)

Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis
by: Ningning Zhang, et al.
Published: (2020-01-01)

hsa_circRNA_012515 Is Highly Expressed in NSCLC Patients and Affects Its Prognosis
by: Fu Y, et al.
Published: (2020-03-01)

Elderly patients with advanced NSCLC: The value of geriatric evaluation and the feasibility of CGA alternatives in predicting chemotherapy toxicity
by: T. Almodovar, et al.
Published: (2019-01-01)

Second-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Single Institution Experience
by: Hanaa Attia, et al.
Published: (2017-06-01)

Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas.
by: Jung Ryul Kim, et al.
Published: (2013-01-01)

The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC
by: Fan, M., et al.
Published: (2021)

The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC
by: Kaikai Shen, et al.
Published: (2021-09-01)

Influence of Programmed Death Ligand-1-Gene Polymorphism rs822336 on the Prognosis and Safety of Postoperative Patients with NSCLC Who Received Platinum-Based Adjuvant Chemotherapy
by: Zhao M, et al.
Published: (2020-08-01)

Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC.
by: Seth A Brodie, et al.
Published: (2014-01-01)

Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC)
by: Nikaedo Sueli M, et al.
Published: (2004-09-01)

Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC
by: Wenpan Peng, et al.
Published: (2021-01-01)

Lower blood calcium associates with unfavorable prognosis and predicts for bone metastasis in NSCLC.
by: Hongchang Shen, et al.
Published: (2012-01-01)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
by: Li Liu, et al.
Published: (2021-06-01)

The Value of 18F-FDG PET in Predicting the Prognosis of NSCLC
by: Yuzhou WANG, et al.
Published: (2009-05-01)